RAG2 and neoplasm: Indeed, low-dose TSA delivery failed to inhibit tumor growth in the RAG2-deficient recipient mice, indicating that adaptive immune cells are required for the anti-tumor responses elicited by low-dose TSA treatment (Fig. 1g, h).